Free Trial

Globus Medical (GMED) Financials

Globus Medical logo
$58.70 -0.52 (-0.87%)
As of 02:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Globus Medical

Annual Income Statements for Globus Medical

This table shows Globus Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders
103 123 190 149 102 155 156 107 104 113
Consolidated Net Income / (Loss)
103 123 190 149 102 155 156 107 104 113
Net Income / (Loss) Continuing Operations
103 123 190 149 102 155 156 107 104 113
Total Pre-Tax Income
121 165 243 180 126 190 189 170 157 173
Total Operating Income
166 133 228 172 111 172 169 162 154 172
Total Gross Profit
1,484 1,020 759 719 572 605 554 486 429 412
Total Revenue
2,519 1,568 1,023 958 789 785 713 636 564 545
Operating Revenue
2,519 1,568 1,023 958 789 785 713 636 564 545
Total Cost of Revenue
1,035 548 264 239 217 180 159 150 135 132
Operating Cost of Revenue
1,035 548 264 239 217 180 159 150 135 132
Total Operating Expenses
1,318 887 531 547 460 433 384 324 275 240
Selling, General & Admin Expense
981 643 432 408 355 355 312 268 222 210
Research & Development Expense
164 124 73 97 85 60 55 44 45 36
Amortization Expense
119 51 18 19 17 14 9.59 7.91 3.48 1.56
Restructuring Charge
53 68 5.96 17 4.03 2.58 1.68 1.61 1.83 3.35
Other Special Charges / (Income)
0.31 0.43 2.34 5.92 0.01 2.19 5.88 2.67 3.16 -11
Total Other Income / (Expense), net
-45 32 15 8.45 14 18 19 8.09 3.14 1.17
Interest Expense
4.19 -20 -14 -9.30 -14 -17 -13 -6.61 -3.06 -1.30
Other Income / (Expense), net
-41 12 0.84 -0.84 0.51 0.55 6.00 1.48 0.08 -0.14
Income Tax Expense
18 43 53 31 24 35 32 63 53 60
Basic Earnings per Share
$0.76 $1.09 $1.89 $1.48 $1.04 $1.57 $1.60 $1.12 $1.09 $1.19
Weighted Average Basic Shares Outstanding
135.73M 113.09M 100.47M 100.73M 98.58M 99.15M 97.88M 96.24M 95.65M 95.05M
Diluted Earnings per Share
$0.75 $1.07 $1.85 $1.44 $1.01 $1.52 $1.54 $1.10 $1.08 $1.17
Weighted Average Diluted Shares Outstanding
137.86M 114.63M 102.64M 103.62M 100.97M 102.00M 101.32M 97.89M 96.43M 96.07M
Weighted Average Basic & Diluted Shares Outstanding
137.54M 135.37M 100.30M 101.56M 99.80M 99.84M 97.80M 95.80M 95.70M 94.80M

Quarterly Income Statements for Globus Medical

This table shows Globus Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
75 27 52 32 -7.12 15 1.00 58 49 50 47
Consolidated Net Income / (Loss)
75 27 52 32 -7.12 15 1.00 58 49 50 47
Net Income / (Loss) Continuing Operations
75 27 52 32 -7.12 15 1.00 58 49 50 47
Total Pre-Tax Income
104 25 57 48 -8.56 25 2.54 75 63 62 61
Total Operating Income
97 60 48 50 8.00 10 0.40 66 56 54 60
Total Gross Profit
403 394 355 370 365 351 248 215 206 204 189
Total Revenue
598 657 626 630 607 617 384 292 277 274 254
Operating Revenue
598 657 626 630 607 617 384 292 277 274 254
Total Cost of Revenue
195 263 271 260 241 265 135 76 71 71 65
Operating Cost of Revenue
195 263 271 260 241 265 135 76 71 71 65
Total Operating Expenses
306 334 307 320 357 341 248 149 149 150 129
Selling, General & Admin Expense
243 253 241 238 249 245 156 120 122 118 107
Research & Development Expense
33 33 35 38 57 52 29 21 21 20 19
Amortization Expense
29 30 30 30 30 28 14 4.55 4.60 4.51 4.32
Restructuring Charge
1.06 17 1.57 13 22 16 46 5.71 1.36 7.79 -0.65
Total Other Income / (Expense), net
6.66 -36 8.93 -2.04 -17 15 2.13 8.46 6.79 8.39 1.76
Interest Expense
-1.68 -0.82 0.78 2.34 1.89 2.58 -7.92 -8.29 -6.50 -5.32 -3.90
Other Income / (Expense), net
4.98 -36 9.71 0.29 -15 17 -5.79 0.17 0.29 3.07 -2.14
Income Tax Expense
28 -1.84 5.20 16 -1.44 9.96 1.54 17 14 12 14
Basic Earnings per Share
$0.55 $0.20 $0.38 $0.23 ($0.05) $0.02 $0.01 $0.57 $0.49 $0.50 $0.48
Weighted Average Basic Shares Outstanding
136.76M 135.73M 135.62M 135.20M 135.36M 113.09M 113.54M 100.37M 100.28M 100.47M 99.65M
Diluted Earnings per Share
$0.54 $0.19 $0.38 $0.23 ($0.05) $0.01 $0.01 $0.57 $0.48 $0.48 $0.47
Weighted Average Diluted Shares Outstanding
139.77M 137.86M 138.06M 136.98M 135.36M 114.63M 115.25M 101.78M 102.20M 102.64M 101.42M
Weighted Average Basic & Diluted Shares Outstanding
135.38M 137.54M 136.17M 135.41M 135.06M 135.37M 137.79M 100.46M 100.33M 100.30M 99.84M

Annual Cash Flow Statements for Globus Medical

This table details how cash moves in and out of Globus Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents
317 317 -43 -46 44 56 21 51 -16 -25
Net Cash From Operating Activities
521 243 178 276 199 172 182 159 148 124
Net Cash From Continuing Operating Activities
521 243 178 276 199 172 182 159 148 124
Net Income / (Loss) Continuing Operations
103 123 190 149 102 155 156 107 104 113
Consolidated Net Income / (Loss)
103 123 190 149 102 155 156 107 104 113
Depreciation Expense
254 145 68 70 63 53 42 42 39 24
Amortization Expense
241 81 5.39 2.78 0.59 -1.09 1.68 2.67 4.07 3.35
Non-Cash Adjustments To Reconcile Net Income
119 52 37 72 72 32 30 28 24 9.87
Changes in Operating Assets and Liabilities, net
-197 -157 -122 -18 -39 -67 -48 -21 -23 -26
Net Cash From Investing Activities
-176 303 -110 -376 -117 -140 -193 -111 -163 -153
Net Cash From Continuing Investing Activities
-176 303 -110 -376 -117 -140 -193 -111 -163 -153
Purchase of Property, Plant & Equipment
-115 -78 -74 -57 -64 -71 -60 -51 -41 -51
Acquisitions
-18 -296 -31 -34 -33 -24 -15 -30 -76 -49
Purchase of Investments
-114 -101 -420 -622 -224 -347 -538 -393 -350 -300
Sale and/or Maturity of Investments
71 778 415 338 203 301 384 363 335 246
Net Cash From Financing Activities
-28 -232 -110 54 -39 24 33 1.63 0.47 4.28
Net Cash From Continuing Financing Activities
-28 -232 -110 54 -39 24 33 1.63 0.47 4.28
Repurchase of Common Equity
-86 -226 -144 0.00 -105 0.00 0.00 - - -
Other Financing Activities, net
58 -6.26 35 54 66 24 33 1.63 0.47 4.28
Effect of Exchange Rate Changes
0.26 2.18 -0.75 -0.81 0.87 -0.16 - 1.98 -1.89 0.15
Cash Income Taxes Paid
159 101 78 45 25 34 31 59 50 57

Quarterly Cash Flow Statements for Globus Medical

This table details how cash moves in and out of Globus Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-323 162 212 56 -113 188 -27 89 67 16 -17
Net Cash From Operating Activities
177 210 204 54 52 105 50 35 53 64 33
Net Cash From Continuing Operating Activities
177 210 204 54 52 105 50 35 53 64 33
Net Income / (Loss) Continuing Operations
75 27 52 32 -7.12 15 1.00 58 49 50 47
Consolidated Net Income / (Loss)
75 27 52 32 -7.12 15 1.00 58 49 50 47
Depreciation Expense
66 68 67 64 55 71 37 18 18 17 18
Amortization Expense
6.29 53 67 60 60 61 19 0.30 0.48 0.94 1.24
Non-Cash Adjustments To Reconcile Net Income
19 50 14 23 32 1.84 28 11 11 8.99 9.39
Changes in Operating Assets and Liabilities, net
10 12 3.28 -124 -88 -44 -35 -52 -26 -13 -43
Net Cash From Investing Activities
131 -104 -15 -10 -47 321 -81 52 11 -60 -63
Net Cash From Continuing Investing Activities
131 -104 -15 -10 -47 321 -81 52 11 -60 -63
Purchase of Property, Plant & Equipment
-36 -17 -42 -28 -29 -23 -22 -18 -16 -18 -12
Acquisitions
-5.00 - -0.10 -4.89 -13 - -293 - -2.66 -30 -
Purchase of Investments
-1.75 -100 -1.19 -4.16 -8.02 - -19 -12 -69 -97 -143
Sale and/or Maturity of Investments
174 13 28 26 2.65 343 253 82 99 86 92
Net Cash From Financing Activities
-635 60 20 8.71 -116 -237 1.43 1.08 2.94 14 13
Net Cash From Continuing Financing Activities
-635 60 20 8.71 -116 -237 1.43 1.08 2.94 14 13
Repayment of Debt
-450 - - - - - - - - - -
Repurchase of Common Equity
-190 -1.00 - -1.47 -83 -226 - - 0.00 - -
Other Financing Activities, net
5.04 61 20 10 -32 -12 1.43 1.08 2.94 14 13
Effect of Exchange Rate Changes
3.54 -4.28 4.07 3.77 -3.31 -0.35 2.12 0.43 -0.03 -0.84 0.48
Cash Income Taxes Paid
7.20 41 46 70 1.97 35 26 37 1.72 20 22

Annual Balance Sheets for Globus Medical

This table presents Globus Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets
5,252 5,086 2,076 1,957 1,679 1,532 1,301 1,079 928 834
Total Current Assets
2,177 1,915 983 865 822 687 631 620 514 545
Cash & Equivalents
784 467 150 193 - - - - 67 60
Short-Term Investments
106 50 296 250 187 116 200 255 223 221
Accounts Receivable
558 503 213 164 142 154 137 117 92 78
Inventories, net
659 848 299 237 229 196 131 108 113 105
Prepaid Expenses
50 45 21 18 18 17 15 11 15 7.35
Current Deferred & Refundable Income Taxes
21 1.64 4.06 1.22 6.42 8.10 7.29 8.72 3.80 47
Plant, Property, & Equipment, net
562 587 244 221 217 200 172 143 124 115
Total Noncurrent Assets
2,513 2,584 849 872 641 645 498 315 290 175
Long-Term Investments
66 75 496 562 359 410 263 56 60 49
Goodwill
1,432 1,435 197 180 157 129 124 124 106 92
Intangible Assets
795 925 64 69 87 79 87 79 62 33
Noncurrent Deferred & Refundable Income Taxes
94 11 49 24 6.62 5.93 14 20 31 0.00
Other Noncurrent Operating Assets
125 139 43 36 32 22 10 7.95 0.93 0.59
Total Liabilities & Shareholders' Equity
5,252 5,086 2,076 1,957 1,679 1,532 1,301 1,079 928 834
Total Liabilities
1,074 1,088 230 216 173 130 115 111 96 119
Total Current Liabilities
856 392 159 140 121 111 96 93 80 83
Short-Term Debt
443 0.00 - - - - - - - -
Accounts Payable
75 57 36 22 18 25 26 25 17 16
Accrued Expenses
261 240 92 91 78 63 60 53 46 54
Current Deferred Revenue
22 18 14 12 8.13 5.40 2.60 0.76 0.00 -
Current Deferred & Payable Income Tax Liabilities
11 3.85 0.99 1.05 1.10 1.06 0.92 3.27 1.91 0.76
Other Current Liabilities
44 73 16 14 15 17 6.83 11 14 12
Total Noncurrent Liabilities
219 696 71 76 52 18 19 18 16 36
Long-Term Debt
0.00 417 0.00 - - - - - - -
Noncurrent Deferred & Payable Income Tax Liabilities
24 84 1.78 4.31 6.20 6.02 8.11 11 7.88 13
Other Noncurrent Operating Liabilities
195 194 69 71 46 12 11 6.98 7.79 23
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
4,177 3,998 1,846 1,741 1,506 1,402 1,186 968 832 715
Total Preferred & Common Equity
4,177 3,998 1,846 1,741 1,506 1,402 1,186 968 832 715
Total Common Equity
4,177 3,998 1,846 1,741 1,506 1,402 1,186 968 832 715
Common Stock
3,031 2,871 631 554 457 357 300 238 212 193
Retained Earnings
1,153 1,137 1,240 1,194 1,045 1,048 893 736 629 525
Accumulated Other Comprehensive Income / (Loss)
-6.86 -10 -25 -6.77 3.96 -2.90 -7.17 -6.91 -8.64 -1.96

Quarterly Balance Sheets for Globus Medical

This table presents Globus Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
4,711 5,086 4,994 4,944 5,356 2,212 2,150 1,977
Total Current Assets
1,710 2,057 1,924 1,829 1,917 1,210 1,070 920
Cash & Equivalents
461 623 410 354 280 306 218 134
Short-Term Investments
0.00 72 83 80 189 306 287 271
Accounts Receivable
535 588 612 534 494 240 223 206
Inventories, net
664 718 770 816 905 336 321 282
Prepaid Expenses
47 51 46 43 48 20 19 24
Current Deferred & Refundable Income Taxes
3.02 5.15 2.50 0.37 1.74 1.76 3.04 2.20
Plant, Property, & Equipment, net
556 568 572 579 607 248 245 236
Total Noncurrent Assets
2,445 2,462 2,498 2,536 2,832 754 834 820
Long-Term Investments
0.00 12 28 51 276 392 480 504
Goodwill
1,433 1,432 1,454 1,451 1,122 199 199 182
Intangible Assets
772 843 867 888 1,262 55 59 54
Noncurrent Deferred & Refundable Income Taxes
117 45 18 11 7.32 62 51 45
Other Noncurrent Operating Assets
123 129 131 135 164 47 45 36
Total Liabilities & Shareholders' Equity
4,711 5,086 4,994 4,944 5,356 2,212 2,150 1,977
Total Liabilities
623 1,017 1,017 1,021 1,169 227 235 212
Total Current Liabilities
385 818 794 786 429 155 168 145
Short-Term Debt
0.00 437 430 424 - - - -
Accounts Payable
73 58 67 50 87 34 40 32
Accrued Expenses
238 255 216 210 222 90 84 88
Current Deferred Revenue
17 21 20 17 18 15 14 12
Current Deferred & Payable Income Tax Liabilities
13 4.17 11 43 34 1.76 16 1.31
Other Current Liabilities
44 43 49 42 68 15 14 11
Total Noncurrent Liabilities
238 199 223 235 740 72 67 67
Noncurrent Deferred & Payable Income Tax Liabilities
47 7.48 27 40 132 5.30 1.37 1.58
Other Noncurrent Operating Liabilities
192 191 196 195 198 67 66 66
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
4,088 4,069 3,976 3,922 4,187 1,985 1,915 1,764
Total Preferred & Common Equity
4,088 4,069 3,976 3,922 4,187 1,985 1,915 1,764
Total Common Equity
4,088 4,069 3,976 3,922 4,187 1,985 1,915 1,764
Common Stock
3,054 2,950 2,914 2,887 2,858 657 645 606
Retained Earnings
1,036 1,126 1,074 1,047 1,348 1,347 1,289 1,190
Accumulated Other Comprehensive Income / (Loss)
-2.17 -6.96 -12 -11 -19 -19 -19 -32

Annual Metrics And Ratios for Globus Medical

This table displays calculated financial ratios and metrics derived from Globus Medical's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics
- - - - - - - - - -
Revenue Growth
60.62% 53.34% 6.76% 21.43% 0.47% 10.15% 12.11% 12.76% 3.53% 14.84%
EBITDA Growth
67.38% 22.55% 24.07% 38.97% -21.76% 2.54% 5.08% 5.58% -1.23% 22.74%
EBIT Growth
-14.01% -36.51% 33.71% 52.85% -35.12% -1.59% 7.35% 5.90% -10.38% 24.59%
NOPAT Growth
43.16% -44.55% 25.44% 57.07% -35.58% 0.04% 37.40% -0.02% -9.02% 21.78%
Net Income Growth
-16.19% -35.39% 27.47% 45.86% -34.10% -0.81% 45.76% 2.88% -7.49% 21.95%
EPS Growth
-29.91% -42.16% 28.47% 42.57% -33.55% -1.30% 40.00% 1.85% -7.69% 20.62%
Operating Cash Flow Growth
113.82% 36.44% -35.40% 38.98% 15.59% -5.32% 14.20% 7.60% 19.21% 56.63%
Free Cash Flow Firm Growth
110.62% -30,147.99% -92.66% 150.77% 21.89% -56.32% 111.98% 335.48% -273.93% -64.64%
Invested Capital Growth
-4.12% 322.59% 22.98% 2.00% 5.81% 16.94% 8.32% 11.87% 33.79% 39.29%
Revenue Q/Q Growth
1.64% 27.89% 2.45% 1.76% 2.84% 2.04% 2.87% 4.00% 1.62% 2.60%
EBITDA Q/Q Growth
-2.21% 29.58% 14.90% -14.40% 7.86% 4.03% -0.99% 1.91% -4.96% 9.84%
EBIT Q/Q Growth
-2.90% -16.89% 20.68% -19.55% 9.24% 3.94% -2.92% 8.96% -12.03% 10.79%
NOPAT Q/Q Growth
61.69% -28.35% 20.08% -20.23% 9.64% 6.35% 7.07% -0.47% -11.77% 9.45%
Net Income Q/Q Growth
12.53% -22.18% 22.52% -20.24% 7.83% 6.00% 8.59% 0.07% -11.31% 9.69%
EPS Q/Q Growth
31.58% -30.52% 21.71% -20.88% 10.99% 4.83% 7.69% 0.00% -10.74% 8.33%
Operating Cash Flow Q/Q Growth
25.46% 20.07% -6.44% -1.40% 14.96% 6.19% -0.30% 13.16% -11.81% 55.35%
Free Cash Flow Firm Q/Q Growth
113.52% 1.41% -65.20% -27.80% 59.00% -16.74% 35.90% -11.95% 16.51% 129.26%
Invested Capital Q/Q Growth
-3.55% -0.78% 5.80% 0.30% -1.50% 0.00% -2.80% -0.15% -1.32% 3.16%
Profitability Metrics
- - - - - - - - - -
Gross Margin
58.90% 65.05% 74.22% 75.03% 72.44% 77.08% 77.64% 76.34% 76.12% 75.71%
EBITDA Margin
24.62% 23.63% 29.57% 25.44% 22.23% 28.55% 30.67% 32.71% 34.94% 36.63%
Operating Margin
6.59% 8.49% 22.29% 17.95% 14.12% 21.90% 23.75% 25.45% 27.33% 31.61%
EBIT Margin
4.96% 9.26% 22.37% 17.86% 14.19% 21.97% 24.59% 25.68% 27.34% 31.59%
Profit (Net Income) Margin
4.09% 7.83% 18.59% 15.57% 12.96% 19.76% 21.95% 16.88% 18.50% 20.70%
Tax Burden Percent
85.31% 74.29% 78.25% 82.70% 81.24% 81.71% 82.96% 63.17% 66.34% 65.27%
Interest Burden Percent
96.65% 113.86% 106.22% 105.43% 112.46% 110.09% 107.57% 104.05% 101.98% 100.42%
Effective Tax Rate
14.69% 25.71% 21.75% 17.30% 18.76% 18.29% 17.04% 36.83% 33.66% 34.73%
Return on Invested Capital (ROIC)
3.78% 4.19% 21.75% 19.53% 12.91% 22.23% 25.07% 20.07% 24.34% 36.41%
ROIC Less NNEP Spread (ROIC-NNEP)
15.00% -0.10% 20.54% 18.75% 11.35% 20.02% 21.97% 18.76% 23.75% 36.30%
Return on Net Nonoperating Assets (RNNOA)
-1.26% 0.02% -11.15% -10.34% -5.88% -10.24% -10.54% -8.14% -10.85% -19.07%
Return on Equity (ROE)
2.52% 4.20% 10.60% 9.19% 7.03% 11.99% 14.53% 11.93% 13.49% 17.34%
Cash Return on Invested Capital (CROIC)
7.99% -119.27% 1.14% 17.54% 7.27% 6.61% 17.08% 8.86% -4.56% 3.57%
Operating Return on Assets (OROA)
2.42% 4.06% 11.34% 9.41% 6.97% 12.18% 14.74% 16.28% 17.51% 22.38%
Return on Assets (ROA)
1.99% 3.43% 9.43% 8.20% 6.37% 10.96% 13.15% 10.70% 11.85% 14.67%
Return on Common Equity (ROCE)
2.52% 4.20% 10.60% 9.19% 7.03% 11.99% 14.53% 11.93% 13.48% 17.34%
Return on Equity Simple (ROE_SIMPLE)
2.47% 3.07% 10.30% 8.57% 6.79% 11.07% 13.20% 11.09% 12.54% 15.77%
Net Operating Profit after Tax (NOPAT)
142 99 178 142 91 141 140 102 102 112
NOPAT Margin
5.62% 6.31% 17.44% 14.84% 11.47% 17.89% 19.70% 16.08% 18.13% 20.63%
Net Nonoperating Expense Percent (NNEP)
-11.22% 4.29% 1.21% 0.78% 1.56% 2.22% 3.10% 1.31% 0.59% 0.11%
Return On Investment Capital (ROIC_SIMPLE)
3.06% 2.24% 9.66% - - - - - - -
Cost of Revenue to Revenue
41.10% 34.95% 25.78% 24.97% 27.56% 22.92% 22.36% 23.66% 23.88% 24.29%
SG&A Expenses to Revenue
38.94% 41.02% 42.25% 42.60% 44.96% 45.17% 43.70% 42.11% 39.39% 38.59%
R&D to Revenue
6.50% 7.91% 7.14% 10.16% 10.71% 7.65% 7.78% 6.87% 7.90% 6.67%
Operating Expenses to Revenue
52.31% 56.56% 51.93% 57.08% 58.32% 55.18% 53.89% 50.90% 48.79% 44.09%
Earnings before Interest and Taxes (EBIT)
125 145 229 171 112 173 175 163 154 172
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
620 371 302 244 175 224 219 208 197 200
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
2.70 1.84 4.02 4.21 4.27 4.17 3.60 4.09 2.86 3.70
Price to Tangible Book Value (P/TBV)
5.78 4.48 4.68 4.91 5.10 4.90 4.37 5.18 3.58 4.49
Price to Revenue (P/Rev)
4.47 4.68 7.25 7.65 8.16 7.45 5.98 6.23 4.22 4.86
Price to Earnings (P/E)
109.36 59.76 38.99 49.11 62.92 37.71 27.24 36.90 22.79 23.49
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.91% 1.67% 2.56% 2.04% 1.59% 2.65% 3.67% 2.71% 4.39% 4.26%
Enterprise Value to Invested Capital (EV/IC)
2.93 1.88 7.16 8.59 7.84 7.53 6.28 6.56 4.21 6.38
Enterprise Value to Revenue (EV/Rev)
4.27 4.57 6.33 6.60 7.16 6.53 5.13 5.55 3.59 4.21
Enterprise Value to EBITDA (EV/EBITDA)
17.33 19.34 21.40 25.93 32.21 22.89 16.74 16.97 10.28 11.50
Enterprise Value to EBIT (EV/EBIT)
86.06 49.34 28.29 36.94 50.47 29.75 20.87 21.62 13.14 13.33
Enterprise Value to NOPAT (EV/NOPAT)
75.91 72.46 36.29 44.45 62.41 36.52 26.05 34.54 19.81 20.40
Enterprise Value to Operating Cash Flow (EV/OCF)
20.65 29.43 36.27 22.88 28.42 29.84 20.15 22.20 13.71 18.50
Enterprise Value to Free Cash Flow (EV/FCFF)
35.92 0.00 690.06 49.47 110.90 122.78 38.24 78.22 0.00 208.08
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.11 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.08 -0.19 -0.54 -0.55 -0.52 -0.51 -0.48 -0.43 -0.46 -0.53
Leverage Ratio
1.26 1.23 1.12 1.12 1.10 1.09 1.10 1.11 1.14 1.18
Compound Leverage Factor
1.22 1.40 1.19 1.18 1.24 1.21 1.19 1.16 1.16 1.19
Debt to Total Capital
9.59% 9.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
9.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 9.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
90.41% 90.55% 100.00% 100.00% 99.99% 100.00% 100.00% 99.99% 99.99% 99.99%
Debt to EBITDA
0.71 1.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
-0.83 -0.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 1.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
3.13 4.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
-3.62 -1.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 4.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
7.46 5.12 21.53 22.44 24.36 29.39 24.66 24.10 17.59 16.26
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.54 4.88 6.18 6.17 6.80 6.17 6.56 6.67 6.43 6.59
Quick Ratio
1.69 2.60 4.14 4.34 2.72 2.42 3.51 4.01 4.79 4.34
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
299 -2,819 9.38 128 51 42 96 45 -19 11
Operating Cash Flow to CapEx
451.05% 311.09% 241.02% 485.56% 312.28% 243.07% 332.09% 310.04% 361.35% 244.30%
Free Cash Flow to Firm to Interest Expense
71.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
124.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
96.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.49 0.44 0.51 0.53 0.49 0.55 0.60 0.63 0.64 0.71
Accounts Receivable Turnover
4.75 4.38 5.42 6.26 5.33 5.39 5.62 6.10 6.65 7.12
Inventory Turnover
1.37 0.96 0.98 1.03 1.02 1.10 1.33 1.36 1.24 1.35
Fixed Asset Turnover
4.39 3.78 4.40 4.38 3.79 4.23 4.53 4.76 4.72 5.91
Accounts Payable Turnover
15.71 11.82 9.09 11.91 10.16 7.13 6.26 7.08 8.06 7.11
Days Sales Outstanding (DSO)
76.85 83.37 67.39 58.31 68.46 67.71 64.95 59.88 54.90 51.29
Days Inventory Outstanding (DIO)
265.67 381.90 370.90 355.62 357.06 332.16 274.38 268.20 295.28 270.59
Days Payable Outstanding (DPO)
23.23 30.89 40.18 30.64 35.93 51.22 58.31 51.57 45.31 51.35
Cash Conversion Cycle (CCC)
319.29 434.38 398.12 383.29 389.59 348.66 281.02 276.51 304.88 270.53
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
3,664 3,822 904 735 721 681 583 538 481 359
Invested Capital Turnover
0.67 0.66 1.25 1.32 1.13 1.24 1.27 1.25 1.34 1.76
Increase / (Decrease) in Invested Capital
-158 2,918 169 14 40 99 45 57 121 101
Enterprise Value (EV)
10,750 7,167 6,473 6,320 5,650 5,132 3,659 3,531 2,026 2,294
Market Capitalization
11,262 7,343 7,415 7,326 6,436 5,853 4,262 3,961 2,377 2,649
Book Value per Share
$30.68 $29.01 $18.49 $17.16 $15.26 $14.11 $12.04 $10.04 $8.68 $7.51
Tangible Book Value per Share
$14.32 $11.89 $15.88 $14.71 $12.79 $12.02 $9.89 $7.94 $6.93 $6.20
Total Capital
4,621 4,415 1,846 1,741 1,506 1,402 1,186 968 832 715
Total Debt
443 417 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 417 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-513 -176 -942 -1,006 -785 -721 -603 -430 -351 -356
Capital Expenditures (CapEx)
115 78 74 57 64 71 55 51 41 51
Debt-free, Cash-free Net Working Capital (DFCFNWC)
875 1,005 378 281 274 265 195 154 143 155
Debt-free Net Working Capital (DFNWC)
1,765 1,523 824 724 701 576 535 527 434 462
Net Working Capital (NWC)
1,321 1,523 824 724 701 576 535 527 434 462
Net Nonoperating Expense (NNE)
39 -24 -12 -6.99 -12 -15 -16 -5.11 -2.08 -0.38
Net Nonoperating Obligations (NNO)
-513 -176 -942 -1,006 -785 -721 -603 -430 -351 -356
Total Depreciation and Amortization (D&A)
495 225 74 73 63 52 43 45 43 27
Debt-free, Cash-free Net Working Capital to Revenue
34.72% 64.09% 36.96% 29.32% 34.76% 33.69% 27.33% 24.15% 25.37% 28.45%
Debt-free Net Working Capital to Revenue
70.05% 97.10% 80.57% 75.60% 88.84% 73.35% 74.98% 82.91% 76.93% 84.83%
Net Working Capital to Revenue
52.45% 97.10% 80.57% 75.60% 88.84% 73.35% 74.98% 82.91% 76.93% 84.83%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.76 $1.09 $1.89 $1.48 $1.04 $1.57 $1.60 $1.12 $1.09 $1.19
Adjusted Weighted Average Basic Shares Outstanding
135.73M 113.09M 100.47M 100.73M 98.58M 99.15M 97.88M 96.24M 95.65M 95.05M
Adjusted Diluted Earnings per Share
$0.75 $1.07 $1.85 $1.44 $1.01 $1.52 $1.54 $1.10 $1.08 $1.17
Adjusted Weighted Average Diluted Shares Outstanding
137.86M 114.63M 102.64M 103.62M 100.97M 102.00M 101.32M 97.89M 96.43M 96.07M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
137.54M 135.37M 100.30M 101.56M 99.80M 99.84M 98.65M 96.73M 95.97M 95.37M
Normalized Net Operating Profit after Tax (NOPAT)
187 150 185 161 94 144 147 105 106 107
Normalized NOPAT Margin
7.44% 9.56% 18.07% 16.82% 11.89% 18.39% 20.58% 16.50% 18.72% 19.69%
Pre Tax Income Margin
4.79% 10.54% 23.76% 18.83% 15.96% 24.19% 26.45% 26.72% 27.89% 31.72%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
29.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
33.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
2.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
6.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
83.30% 183.57% 75.98% 0.00% 102.33% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Globus Medical

This table displays calculated financial ratios and metrics derived from Globus Medical's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-1.41% 6.61% 63.10% 115.93% 119.26% 124.60% 50.95% 10.61% 20.01% 9.79% 10.63%
EBITDA Growth
60.03% -8.79% 276.51% 105.04% 44.72% 112.89% -33.21% -2.02% 16.57% 109.75% 9.54%
EBIT Growth
1,630.42% -13.50% 1,173.48% -24.80% -111.75% -51.71% -109.35% -2.47% 23.10% 219.20% 9.97%
NOPAT Growth
1,161.39% 963.68% 27,385.65% -35.27% -87.23% -86.02% -99.65% -2.44% 21.23% 214.05% -0.36%
Net Income Growth
1,160.31% 76.30% 5,093.99% -44.97% -114.49% -69.97% -97.90% 5.72% 29.00% 231.42% 0.47%
EPS Growth
1,180.00% 1,800.00% 3,700.00% -59.65% -110.42% -97.92% -97.87% 7.55% 29.73% 220.00% 4.44%
Operating Cash Flow Growth
238.44% 100.95% 303.40% 54.90% -1.74% 63.62% 53.35% -5.03% 19.30% -16.10% -57.39%
Free Cash Flow Firm Growth
110.41% 107.64% 103.21% -2,461.71% -2,309.60% -2,220.88% -3,868.12% -181.37% -2,618.06% -22,053.07% -268.00%
Invested Capital Growth
-6.06% -4.12% -1.37% 296.25% 314.94% 322.59% 350.61% 19.98% 21.59% 22.98% 16.58%
Revenue Q/Q Growth
-9.00% 5.05% -0.63% 3.80% -1.60% 60.71% 31.56% 5.39% 0.80% 8.01% -3.60%
EBITDA Q/Q Growth
19.79% -24.22% 10.51% 59.52% -31.72% 212.80% -39.82% 12.59% 0.44% -1.87% -11.71%
EBIT Q/Q Growth
327.58% -58.74% 15.81% 849.04% -124.17% 612.09% -108.11% 17.09% -0.72% -0.81% -15.42%
NOPAT Q/Q Growth
9.03% 48.15% 31.98% 491.69% -8.06% 3,728.22% -99.69% 16.69% 0.71% -5.48% -12.16%
Net Income Q/Q Growth
184.71% -48.87% 63.21% 546.26% -147.34% 1,406.41% -98.27% 17.47% -1.87% 5.55% -13.11%
EPS Q/Q Growth
184.21% -50.00% 65.22% 560.00% -600.00% 0.00% -98.25% 18.75% 0.00% 2.13% -11.32%
Operating Cash Flow Q/Q Growth
-15.71% 3.28% 275.34% 3.57% -49.95% 107.34% 44.12% -34.30% -16.67% 94.33% -10.74%
Free Cash Flow Firm Q/Q Growth
36.90% 130.97% 103.35% 1.79% -0.45% 2.85% -2,573.02% 7.62% 3.25% -66.10% -89.54%
Invested Capital Q/Q Growth
-1.03% -3.55% -2.23% 0.66% 1.01% -0.78% 292.79% 5.41% 2.87% 5.80% 4.58%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
67.33% 59.92% 56.77% 58.70% 60.19% 56.94% 64.71% 73.78% 74.40% 74.28% 74.23%
EBITDA Margin
29.15% 22.14% 30.70% 27.60% 17.96% 25.88% 13.30% 29.07% 27.21% 27.31% 30.05%
Operating Margin
16.22% 9.17% 7.69% 7.88% 1.32% 1.64% 0.11% 22.71% 20.39% 19.68% 23.49%
EBIT Margin
17.05% 3.63% 9.24% 7.93% -1.10% 4.47% -1.40% 22.76% 20.49% 20.80% 22.65%
Profit (Net Income) Margin
12.62% 4.03% 8.28% 5.04% -1.17% 2.44% 0.26% 19.79% 17.76% 18.24% 18.66%
Tax Burden Percent
72.79% 107.45% 90.89% 66.75% 83.16% 60.15% 39.37% 77.29% 77.75% 80.60% 77.17%
Interest Burden Percent
101.65% 103.42% 98.66% 95.32% 128.42% 90.64% -47.08% 112.49% 111.46% 108.78% 106.77%
Effective Tax Rate
27.21% -7.45% 9.11% 33.25% 0.00% 39.85% 60.63% 22.71% 22.25% 19.40% 22.83%
Return on Invested Capital (ROIC)
7.92% 6.63% 4.53% 4.83% 0.73% 0.66% 0.02% 21.41% 19.98% 19.79% 22.79%
ROIC Less NNEP Spread (ROIC-NNEP)
6.06% 17.74% 1.84% 5.08% 3.16% -0.95% -0.11% 20.72% 19.46% 19.12% 22.65%
Return on Net Nonoperating Assets (RNNOA)
-0.40% -1.49% -0.14% -0.93% -0.57% 0.18% 0.02% -10.61% -10.54% -10.38% -12.32%
Return on Equity (ROE)
7.52% 5.14% 4.39% 3.90% 0.16% 0.84% 0.05% 10.80% 9.44% 9.41% 10.47%
Cash Return on Invested Capital (CROIC)
11.67% 7.99% 3.66% -117.68% -119.80% -119.27% -121.49% 2.38% 2.46% 1.14% 3.39%
Operating Return on Assets (OROA)
8.87% 1.77% 4.39% 4.92% -0.59% 1.96% -0.47% 12.10% 10.56% 10.55% 11.64%
Return on Assets (ROA)
6.56% 1.97% 3.93% 3.13% -0.63% 1.07% 0.09% 10.52% 9.15% 9.25% 9.59%
Return on Common Equity (ROCE)
7.52% 5.14% 4.39% 3.90% 0.16% 0.84% 0.05% 10.80% 9.44% 9.41% 10.47%
Return on Equity Simple (ROE_SIMPLE)
4.54% 0.00% 2.25% 1.02% 1.70% 0.00% 3.77% 10.29% 10.51% 0.00% 8.80%
Net Operating Profit after Tax (NOPAT)
71 65 44 33 5.60 6.09 0.16 51 44 44 46
NOPAT Margin
11.81% 9.85% 6.99% 5.26% 0.92% 0.99% 0.04% 17.55% 15.85% 15.86% 18.13%
Net Nonoperating Expense Percent (NNEP)
1.86% -11.11% 2.68% -0.25% -2.43% 1.60% 0.13% 0.69% 0.53% 0.67% 0.14%
Return On Investment Capital (ROIC_SIMPLE)
1.73% 1.40% - - - 0.14% - - - 2.36% -
Cost of Revenue to Revenue
32.67% 40.08% 43.23% 41.30% 39.81% 43.06% 35.29% 26.22% 25.60% 25.72% 25.77%
SG&A Expenses to Revenue
40.59% 38.56% 38.47% 37.82% 41.00% 39.69% 40.72% 41.17% 44.24% 43.01% 41.93%
R&D to Revenue
5.53% 5.08% 5.65% 5.99% 9.44% 8.48% 7.64% 7.32% 7.62% 7.11% 7.36%
Operating Expenses to Revenue
51.11% 50.75% 49.08% 50.82% 58.88% 55.30% 64.60% 51.07% 54.02% 54.60% 50.74%
Earnings before Interest and Taxes (EBIT)
102 24 58 50 -6.66 28 -5.39 66 57 57 58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
174 146 192 174 109 160 51 85 75 75 76
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.46 2.70 2.38 2.33 1.88 1.84 1.19 3.01 2.97 4.02 3.36
Price to Tangible Book Value (P/TBV)
5.35 5.78 5.40 5.59 4.67 4.48 2.77 3.45 3.43 4.68 3.88
Price to Revenue (P/Rev)
4.01 4.47 3.91 4.14 3.89 4.68 4.07 5.45 5.31 7.25 5.94
Price to Earnings (P/E)
54.26 109.36 105.85 227.41 110.93 59.76 31.59 29.24 28.23 38.99 38.19
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
1.84% 0.91% 0.94% 0.44% 0.90% 1.67% 3.17% 3.42% 3.54% 2.56% 2.62%
Enterprise Value to Invested Capital (EV/IC)
2.65 2.93 2.48 2.36 1.90 1.88 1.21 5.07 5.05 7.16 5.87
Enterprise Value to Revenue (EV/Rev)
3.83 4.27 3.80 4.10 3.86 4.57 3.79 4.53 4.39 6.33 5.03
Enterprise Value to EBITDA (EV/EBITDA)
14.01 17.33 14.84 18.57 18.13 19.34 16.27 15.96 15.00 21.40 19.07
Enterprise Value to EBIT (EV/EBIT)
41.13 86.06 73.21 139.97 89.49 49.34 26.62 20.90 19.62 28.29 26.47
Enterprise Value to NOPAT (EV/NOPAT)
47.29 75.91 107.53 219.93 121.58 72.46 33.70 26.90 25.25 36.29 33.78
Enterprise Value to Operating Cash Flow (EV/OCF)
14.88 20.65 22.69 34.99 30.22 29.43 22.94 26.83 25.10 36.27 26.31
Enterprise Value to Free Cash Flow (EV/FCFF)
21.98 35.92 67.19 0.00 0.00 0.00 0.00 231.97 225.65 690.06 186.19
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.11 0.11 0.11 0.11 0.10 0.10 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.10 0.10 0.00 0.00 0.00 0.00
Financial Leverage
-0.07 -0.08 -0.07 -0.18 -0.18 -0.19 -0.21 -0.51 -0.54 -0.54 -0.54
Leverage Ratio
1.21 1.26 1.26 1.21 1.22 1.23 1.23 1.12 1.12 1.12 1.12
Compound Leverage Factor
1.23 1.31 1.25 1.15 1.56 1.11 -0.58 1.26 1.25 1.22 1.19
Debt to Total Capital
0.00% 9.59% 9.70% 9.77% 9.76% 9.45% 8.91% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 9.59% 9.70% 9.77% 9.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 9.45% 8.91% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 90.41% 90.30% 90.23% 90.24% 90.55% 91.09% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.71 0.69 0.87 1.05 1.13 1.43 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 -0.83 -0.43 -0.18 -0.15 -0.47 -1.17 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 1.13 1.43 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 3.13 4.99 10.34 7.03 4.22 2.97 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 -3.62 -3.08 -2.17 -1.02 -1.78 -2.43 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 4.22 2.97 0.00 0.00 0.00 0.00
Altman Z-Score
10.95 7.39 6.84 6.51 5.27 5.05 3.47 17.78 16.45 21.26 18.66
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.45 2.54 2.51 2.42 2.33 4.88 4.47 7.80 6.39 6.18 6.33
Quick Ratio
2.59 1.69 1.57 1.39 1.23 2.60 2.25 5.50 4.34 4.14 4.21
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
304 222 96 -2,872 -2,925 -2,912 -2,997 -112 -121 -125 -76
Operating Cash Flow to CapEx
491.09% 1,229.26% 485.45% 195.19% 183.38% 457.47% 234.44% 196.04% 333.39% 348.83% 274.72%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 124.25 -1,230.10 -1,544.17 -1,128.09 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 262.78 23.24 27.66 40.56 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 208.65 11.33 12.58 31.69 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.52 0.49 0.47 0.62 0.54 0.44 0.33 0.53 0.52 0.51 0.51
Accounts Receivable Turnover
4.70 4.75 4.58 5.25 5.02 4.38 3.50 5.07 5.50 5.42 5.46
Inventory Turnover
1.34 1.37 1.28 1.63 1.26 0.96 0.60 0.94 0.96 0.98 0.99
Fixed Asset Turnover
4.42 4.39 4.22 5.46 4.61 3.78 2.91 4.51 4.52 4.40 4.42
Accounts Payable Turnover
16.01 15.71 14.36 17.87 15.92 11.82 5.94 8.33 8.35 9.09 9.68
Days Sales Outstanding (DSO)
77.73 76.85 79.68 69.52 72.78 83.37 104.23 72.04 66.41 67.39 66.88
Days Inventory Outstanding (DIO)
272.96 265.67 285.43 223.68 288.72 381.90 613.39 387.43 381.01 370.90 369.95
Days Payable Outstanding (DPO)
22.80 23.23 25.41 20.42 22.93 30.89 61.43 43.80 43.69 40.18 37.69
Cash Conversion Cycle (CCC)
327.89 319.29 339.70 272.78 338.57 434.38 656.19 415.67 403.73 398.12 399.14
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
3,627 3,664 3,800 3,886 3,861 3,822 3,852 981 930 904 855
Invested Capital Turnover
0.67 0.67 0.65 0.92 0.79 0.66 0.52 1.22 1.26 1.25 1.26
Increase / (Decrease) in Invested Capital
-234 -158 -53 2,905 2,930 2,918 2,997 163 165 169 122
Enterprise Value (EV)
9,607 10,750 9,417 9,160 7,330 7,167 4,653 4,970 4,697 6,473 5,019
Market Capitalization
10,068 11,262 9,687 9,250 7,391 7,343 4,988 5,974 5,681 7,415 5,928
Book Value per Share
$29.72 $30.68 $30.05 $29.44 $28.98 $29.01 $41.68 $19.78 $19.09 $18.49 $17.73
Tangible Book Value per Share
$13.69 $14.32 $13.26 $12.26 $11.70 $11.89 $17.95 $17.25 $16.52 $15.88 $15.36
Total Capital
4,088 4,621 4,507 4,407 4,346 4,415 4,597 1,985 1,915 1,846 1,764
Total Debt
0.00 443 437 430 424 417 410 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 417 410 0.00 0.00 0.00 0.00
Net Debt
-461 -513 -270 -90 -62 -176 -335 -1,004 -984 -942 -909
Capital Expenditures (CapEx)
36 17 42 28 29 23 22 18 16 18 12
Debt-free, Cash-free Net Working Capital (DFCFNWC)
864 875 981 1,067 1,032 1,005 1,020 442 399 378 369
Debt-free Net Working Capital (DFNWC)
1,325 1,765 1,676 1,560 1,466 1,523 1,489 1,055 903 824 775
Net Working Capital (NWC)
1,325 1,321 1,238 1,130 1,042 1,523 1,489 1,055 903 824 775
Net Nonoperating Expense (NNE)
-4.85 38 -8.12 1.36 13 -8.95 -0.84 -6.54 -5.28 -6.52 -1.36
Net Nonoperating Obligations (NNO)
-461 -513 -270 -90 -62 -176 -335 -1,004 -984 -942 -909
Total Depreciation and Amortization (D&A)
72 122 134 124 116 132 56 18 19 18 19
Debt-free, Cash-free Net Working Capital to Revenue
34.42% 34.72% 39.57% 47.72% 54.35% 64.09% 83.14% 40.29% 37.28% 36.96% 37.01%
Debt-free Net Working Capital to Revenue
52.79% 70.05% 67.60% 69.76% 77.24% 97.10% 121.38% 96.16% 84.46% 80.57% 77.60%
Net Working Capital to Revenue
52.79% 52.45% 49.97% 50.51% 54.90% 97.10% 121.38% 96.16% 84.46% 80.57% 77.60%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.55 $0.20 $0.38 $0.23 ($0.05) $0.02 $0.01 $0.57 $0.49 $0.50 $0.48
Adjusted Weighted Average Basic Shares Outstanding
136.76M 135.73M 135.62M 135.20M 135.36M 113.09M 113.54M 100.37M 100.28M 100.47M 99.65M
Adjusted Diluted Earnings per Share
$0.54 $0.19 $0.38 $0.23 ($0.05) $0.01 $0.01 $0.57 $0.48 $0.48 $0.47
Adjusted Weighted Average Diluted Shares Outstanding
139.77M 137.86M 138.06M 136.98M 135.36M 114.63M 115.25M 101.78M 102.20M 102.64M 101.42M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
135.38M 137.54M 136.17M 135.41M 135.06M 135.37M 137.79M 100.46M 100.33M 100.30M 99.84M
Normalized Net Operating Profit after Tax (NOPAT)
71 54 45 43 21 16 34 53 45 50 46
Normalized NOPAT Margin
11.93% 8.21% 7.12% 6.80% 3.41% 2.53% 8.93% 18.33% 16.23% 18.15% 17.93%
Pre Tax Income Margin
17.33% 3.75% 9.11% 7.56% -1.41% 4.05% 0.66% 25.61% 22.84% 22.63% 24.18%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 74.59 21.38 -3.52 10.68 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 56.41 14.19 2.96 2.36 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 20.46 9.47 -18.60 1.82 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 2.28 2.28 -12.13 -6.51 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
103.97% 83.30% 339.13% 763.00% 463.59% 183.57% 0.00% 0.00% 0.00% 75.98% 93.09%

Frequently Asked Questions About Globus Medical's Financials

When does Globus Medical's fiscal year end?

According to the most recent income statement we have on file, Globus Medical's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Globus Medical's net income changed over the last 9 years?

Globus Medical's net income were at $102.98 million at the end of 2024, a 16.2% decrease from 2023, and a 8.7% decrease since 2015. View Globus Medical's forecast to see where analysts expect Globus Medical to go next.

What is Globus Medical's operating income?
Globus Medical's total operating income in 2024 was $165.99 million, based on the following breakdown:
  • Total Gross Profit: $1.48 billion
  • Total Operating Expenses: $1.32 billion
How has Globus Medical revenue changed over the last 9 years?

Over the last 9 years, Globus Medical's total revenue changed from $544.75 million in 2015 to $2.52 billion in 2024, a change of 362.5%.

How much debt does Globus Medical have?

Globus Medical's total liabilities were at $1.07 billion at the end of 2024, a 1.3% decrease from 2023, and a 804.6% increase since 2015.

How much cash does Globus Medical have?

In the past 9 years, Globus Medical's cash and equivalents has ranged from $0.00 in 2017 to $784.44 million in 2024, and is currently $784.44 million as of their latest financial filing in 2024.

How has Globus Medical's book value per share changed over the last 9 years?

Over the last 9 years, Globus Medical's book value per share changed from 7.51 in 2015 to 30.68 in 2024, a change of 308.5%.



This page (NYSE:GMED) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners